Click here to get full coverage on SMMT warns HGV decarbonisation lagging behind targets despite growing investment - The Manufacturer

SMMT warns HGV decarbonisation lagging behind targets despite growing investment  The Manufacturer

SMMT warns HGV decarbonisation lagging behind targets despite growing investment - The Manufacturer

Click here to get full coverage on Summit Therapeutics (SMMT) Added to Citi 90-Day Upside Catalyst Call List - StreetInsider

Summit Therapeutics (SMMT) Added to Citi 90-Day Upside Catalyst Call List  StreetInsider

Summit Therapeutics (SMMT) Added to Citi 90-Day Upside Catalyst Call List - StreetInsider

Click here to get full coverage on Summit Therapeutics Inc. (SMMT) focused on non-small cell lung cancer trial of Ivonescimab - MSN

Summit Therapeutics Inc. (SMMT) focused on non-small cell lung cancer trial of Ivonescimab  MSN

Summit Therapeutics Inc. (SMMT) focused on non-small cell lung cancer trial of Ivonescimab - MSN

Click here to get full coverage on Summit Therapeutics (SMMT) Ends 2025 With Strong Cash Reserves and Increased Clinical Investment - Yahoo Finance

Summit Therapeutics (SMMT) Ends 2025 With Strong Cash Reserves and Increased Clinical Investment  Yahoo Finance

Summit Therapeutics (SMMT) Ends 2025 With Strong Cash Reserves and Increased Clinical Investment - Yahoo Finance

Click here to get full coverage on Vanguard Group Inc. Purchases 2,706,056 Shares of Summit Therapeutics PLC $SMMT - MarketBeat

Vanguard Group Inc. Purchases 2,706,056 Shares of Summit Therapeutics PLC $SMMT  MarketBeat

Vanguard Group Inc. Purchases 2,706,056 Shares of Summit Therapeutics PLC $SMMT - MarketBeat

Click here to get full coverage on Should Jefferies’ Downgrade and Ivonesimab Focus Shape Summit Therapeutics’ (SMMT) Risk‑Reward Profile? - simplywall.st

Should Jefferies’ Downgrade and Ivonesimab Focus Shape Summit Therapeutics’ (SMMT) Risk‑Reward Profile?  simplywall.st

Should Jefferies’ Downgrade and Ivonesimab Focus Shape Summit Therapeutics’ (SMMT) Risk‑Reward Profile? - simplywall.st

Click here to get full coverage on Is Summit Therapeutics (SMMT) Pricing Reflect Long Term Value After Recent Share Price Swings - Yahoo Finance

Is Summit Therapeutics (SMMT) Pricing Reflect Long Term Value After Recent Share Price Swings  Yahoo Finance

Is Summit Therapeutics (SMMT) Pricing Reflect Long Term Value After Recent Share Price Swings - Yahoo Finance

Click here to get full coverage on Is Summit Therapeutics (SMMT) Now Pricing In Too Much Hope After Strong Multi Year Gains - simplywall.st

Is Summit Therapeutics (SMMT) Now Pricing In Too Much Hope After Strong Multi Year Gains  simplywall.st

Is Summit Therapeutics (SMMT) Now Pricing In Too Much Hope After Strong Multi Year Gains - simplywall.st

Click here to get full coverage on Summit Therapeutics (SMMT) Valuation Check After Recent Share Price Pullback And Conflicting Model Signals - Yahoo Finance

Summit Therapeutics (SMMT) Valuation Check After Recent Share Price Pullback And Conflicting Model Signals  Yahoo Finance

Summit Therapeutics (SMMT) Valuation Check After Recent Share Price Pullback And Conflicting Model Signals - Yahoo Finance

Click here to get full coverage on Summit Therapeutics (SMMT) Grabs Investor Attention After Major FDA Breakthrough - Yahoo Finance

Summit Therapeutics (SMMT) Grabs Investor Attention After Major FDA Breakthrough  Yahoo Finance

Summit Therapeutics (SMMT) Grabs Investor Attention After Major FDA Breakthrough - Yahoo Finance

Click here to get full coverage on Is Summit Therapeutics (SMMT) Still Attractive After Recent Pullback And Multi Year Surge - Yahoo Finance

Is Summit Therapeutics (SMMT) Still Attractive After Recent Pullback And Multi Year Surge  Yahoo Finance

Is Summit Therapeutics (SMMT) Still Attractive After Recent Pullback And Multi Year Surge - Yahoo Finance

Click here to get full coverage on A Look At Summit Therapeutics (SMMT) Valuation After Recent Share Price Strength - Yahoo Finance

A Look At Summit Therapeutics (SMMT) Valuation After Recent Share Price Strength  Yahoo Finance

A Look At Summit Therapeutics (SMMT) Valuation After Recent Share Price Strength - Yahoo Finance

Click here to get full coverage on Summit Therapeutics (SMMT) Is Up 7.6% After Steep Losses And New US$102 Million Shelf Registration - Has The Bull Case Changed? - Yahoo Finance

Summit Therapeutics (SMMT) Is Up 7.6% After Steep Losses And New US$102 Million Shelf Registration - Has The Bull Case Changed?  Yahoo Finance

Summit Therapeutics (SMMT) Is Up 7.6% After Steep Losses And New US$102 Million Shelf Registration - Has The Bull Case Changed? - Yahoo Finance

Click here to get full coverage on FDA Accepts Summit Therapeutics’ (SMMT) BLA For Ivonescimab In NSCLC With November 14 PDUFA Date Following Positive Phase III Data - Yahoo Finance

FDA Accepts Summit Therapeutics’ (SMMT) BLA For Ivonescimab In NSCLC With November 14 PDUFA Date Following Positive Phase III Data  Yahoo Finance

FDA Accepts Summit Therapeutics’ (SMMT) BLA For Ivonescimab In NSCLC With November 14 PDUFA Date Following Positive Phase III Data - Yahoo Finance

Click here to get full coverage on Summit Therapeutics (SMMT) Is Down 8.7% After Ivonescimab BLA Filing And Oncology Expansion Update – Has The Bull Case Changed? - Yahoo Finance

Summit Therapeutics (SMMT) Is Down 8.7% After Ivonescimab BLA Filing And Oncology Expansion Update – Has The Bull Case Changed?  Yahoo Finance

Summit Therapeutics (SMMT) Is Down 8.7% After Ivonescimab BLA Filing And Oncology Expansion Update – Has The Bull Case Changed? - Yahoo Finance

Click here to get full coverage on Summit Therapeutics (SMMT): Valuation Check After Weak Q3 2025 Results and Insider Share Purchases - Yahoo Finance

Summit Therapeutics (SMMT): Valuation Check After Weak Q3 2025 Results and Insider Share Purchases  Yahoo Finance

Summit Therapeutics (SMMT): Valuation Check After Weak Q3 2025 Results and Insider Share Purchases - Yahoo Finance

Click here to get full coverage on Citi Asserts Buy Rating on Summit Therapeutics Inc. (SMMT) on Pipeline Development - Yahoo Finance

Citi Asserts Buy Rating on Summit Therapeutics Inc. (SMMT) on Pipeline Development  Yahoo Finance

Citi Asserts Buy Rating on Summit Therapeutics Inc. (SMMT) on Pipeline Development - Yahoo Finance

Click here to get full coverage on Is Summit Therapeutics (SMMT) Pricing Reflecting Its Recent Share Price Pullback Accurately - Yahoo Finance

Is Summit Therapeutics (SMMT) Pricing Reflecting Its Recent Share Price Pullback Accurately  Yahoo Finance

Is Summit Therapeutics (SMMT) Pricing Reflecting Its Recent Share Price Pullback Accurately - Yahoo Finance

Click here to get full coverage on Summit Therapeutics (SMMT) Is Down 6.4% After $513M Shelf Filing and Ivonescimab Clinical Updates—Has The Bull Case Changed? - Yahoo Finance

Summit Therapeutics (SMMT) Is Down 6.4% After $513M Shelf Filing and Ivonescimab Clinical Updates—Has The Bull Case Changed?  Yahoo Finance

Summit Therapeutics (SMMT) Is Down 6.4% After $513M Shelf Filing and Ivonescimab Clinical Updates—Has The Bull Case Changed? - Yahoo Finance

Click here to get full coverage on Is Summit Therapeutics Inc. (SMMT) One of the Most Oversold NASDAQ Stocks to Invest In? - Yahoo Finance

Is Summit Therapeutics Inc. (SMMT) One of the Most Oversold NASDAQ Stocks to Invest In?  Yahoo Finance

Is Summit Therapeutics Inc. (SMMT) One of the Most Oversold NASDAQ Stocks to Invest In? - Yahoo Finance

Click here to get full coverage on Cantor Fitzgerald Reaffirms Overweight Rating on Summit Therapeutics (SMMT) Before Key 2026 Catalyst - Yahoo Finance

Cantor Fitzgerald Reaffirms Overweight Rating on Summit Therapeutics (SMMT) Before Key 2026 Catalyst  Yahoo Finance

Cantor Fitzgerald Reaffirms Overweight Rating on Summit Therapeutics (SMMT) Before Key 2026 Catalyst - Yahoo Finance

Click here to get full coverage on A Look at Summit Therapeutics (SMMT) Valuation Following Positive HARMONi Trial Results and Regulatory Progress - Yahoo Finance

A Look at Summit Therapeutics (SMMT) Valuation Following Positive HARMONi Trial Results and Regulatory Progress  Yahoo Finance

A Look at Summit Therapeutics (SMMT) Valuation Following Positive HARMONi Trial Results and Regulatory Progress - Yahoo Finance

Click here to get full coverage on Where is Summit Therapeutics (SMMT) Headed According to Analysts? - Yahoo Finance

Where is Summit Therapeutics (SMMT) Headed According to Analysts?  Yahoo Finance

Where is Summit Therapeutics (SMMT) Headed According to Analysts? - Yahoo Finance

Click here to get full coverage on Summit Therapeutics (SMMT): A Valuation Perspective After Recent 16% Share Price Climb - Yahoo Finance

Summit Therapeutics (SMMT): A Valuation Perspective After Recent 16% Share Price Climb  Yahoo Finance

Summit Therapeutics (SMMT): A Valuation Perspective After Recent 16% Share Price Climb - Yahoo Finance

Click here to get full coverage on Summit Therapeutics gives 17 new hires options on 214,331 shares - Stock Titan

Summit Therapeutics gives 17 new hires options on 214,331 shares  Stock Titan

Summit Therapeutics gives 17 new hires options on 214,331 shares - Stock Titan

Click here to get full coverage on Summit Therapeutics Inc (SMMT) Q3 2025 Earnings Call Highlights: Promising Clinical ... - Yahoo Finance

Summit Therapeutics Inc (SMMT) Q3 2025 Earnings Call Highlights: Promising Clinical ...  Yahoo Finance

Summit Therapeutics Inc (SMMT) Q3 2025 Earnings Call Highlights: Promising Clinical ... - Yahoo Finance

Click here to get full coverage on Summit Therapeutics (SMMT) Reports Positive Results from the Phase III HARMONi Trial - Yahoo Finance

Summit Therapeutics (SMMT) Reports Positive Results from the Phase III HARMONi Trial  Yahoo Finance

Summit Therapeutics (SMMT) Reports Positive Results from the Phase III HARMONi Trial - Yahoo Finance

Click here to get full coverage on Busiest February for new cars since 2004 but EV demand idles - SMMT

Busiest February for new cars since 2004 but EV demand idles  SMMT

Busiest February for new cars since 2004 but EV demand idles - SMMT

Click here to get full coverage on November new car market struggles ahead of Budget drag on demand - SMMT

November new car market struggles ahead of Budget drag on demand  SMMT

November new car market struggles ahead of Budget drag on demand - SMMT

Click here to get full coverage on Summit Therapeutics (SMMT) Expands its Phase 3 Trials for Ivonescimab - Yahoo Finance

Summit Therapeutics (SMMT) Expands its Phase 3 Trials for Ivonescimab  Yahoo Finance

Summit Therapeutics (SMMT) Expands its Phase 3 Trials for Ivonescimab - Yahoo Finance

Click here to get full coverage on FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug - Yahoo Finance

FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug  Yahoo Finance

FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug - Yahoo Finance

Click here to get full coverage on Summit Therapeutics Inc. (SMMT) Highlights Ivonescimab Progress at WCLC 2025 - Yahoo Finance

Summit Therapeutics Inc. (SMMT) Highlights Ivonescimab Progress at WCLC 2025  Yahoo Finance

Summit Therapeutics Inc. (SMMT) Highlights Ivonescimab Progress at WCLC 2025 - Yahoo Finance

Click here to get full coverage on A Look at Summit Therapeutics (SMMT) Valuation Following Phase III Trial Setback and Legal Investigation - Yahoo Finance

A Look at Summit Therapeutics (SMMT) Valuation Following Phase III Trial Setback and Legal Investigation  Yahoo Finance

A Look at Summit Therapeutics (SMMT) Valuation Following Phase III Trial Setback and Legal Investigation - Yahoo Finance

Click here to get full coverage on H.C. Wainwright Lifts PT on Summit Therapeutics (SMMT) to $50 From $44 - Yahoo Finance

H.C. Wainwright Lifts PT on Summit Therapeutics (SMMT) to $50 From $44  Yahoo Finance

H.C. Wainwright Lifts PT on Summit Therapeutics (SMMT) to $50 From $44 - Yahoo Finance

Click here to get full coverage on Guggenheim Initiates Summit Therapeutics (SMMT) With a Buy Rating - Yahoo Finance

Guggenheim Initiates Summit Therapeutics (SMMT) With a Buy Rating  Yahoo Finance

Guggenheim Initiates Summit Therapeutics (SMMT) With a Buy Rating - Yahoo Finance

Click here to get full coverage on SMMT warns EV targets risk ‘deindustrialisation’ without policy review - Energy Live News

SMMT warns EV targets risk ‘deindustrialisation’ without policy review  Energy Live News

SMMT warns EV targets risk ‘deindustrialisation’ without policy review - Energy Live News

Click here to get full coverage on Summit Therapeutics Inc. (SMMT) Faces Volatile 2025 as Ivonescimab Gains Approval in China - Yahoo Finance

Summit Therapeutics Inc. (SMMT) Faces Volatile 2025 as Ivonescimab Gains Approval in China  Yahoo Finance

Summit Therapeutics Inc. (SMMT) Faces Volatile 2025 as Ivonescimab Gains Approval in China - Yahoo Finance

Click here to get full coverage on Summit Therapeutics (NASDAQ:SMMT) Rating Lowered to "Hold" at Jefferies Financial Group - MarketBeat

Summit Therapeutics (NASDAQ:SMMT) Rating Lowered to "Hold" at Jefferies Financial Group  MarketBeat

Summit Therapeutics (NASDAQ:SMMT) Rating Lowered to "Hold" at Jefferies Financial Group - MarketBeat

Click here to get full coverage on New car market holds steady in October but new tax policy threatens market decline - SMMT

New car market holds steady in October but new tax policy threatens market decline  SMMT

New car market holds steady in October but new tax policy threatens market decline - SMMT

Click here to get full coverage on New car market starts year with growth but EV share falls - SMMT

New car market starts year with growth but EV share falls  SMMT

New car market starts year with growth but EV share falls - SMMT

Click here to get full coverage on SMMT's Q3 Loss Wider Than Expected, Stock Down on Study Amendments - Yahoo Finance

SMMT's Q3 Loss Wider Than Expected, Stock Down on Study Amendments  Yahoo Finance

SMMT's Q3 Loss Wider Than Expected, Stock Down on Study Amendments - Yahoo Finance

Click here to get full coverage on H.C. Wainwright Reaffirms Price Target for Summit Therapeutics (SMMT) After Ivonescimab Milestones - Yahoo Finance

H.C. Wainwright Reaffirms Price Target for Summit Therapeutics (SMMT) After Ivonescimab Milestones  Yahoo Finance

H.C. Wainwright Reaffirms Price Target for Summit Therapeutics (SMMT) After Ivonescimab Milestones - Yahoo Finance

Click here to get full coverage on SMMT: UK vehicle production hit 73-year low in 2025 - Automotive World

SMMT: UK vehicle production hit 73-year low in 2025  Automotive World

SMMT: UK vehicle production hit 73-year low in 2025 - Automotive World

Click here to get full coverage on UK new car market sees slight rise in October, SMMT data shows - Reuters

UK new car market sees slight rise in October, SMMT data shows  Reuters

UK new car market sees slight rise in October, SMMT data shows - Reuters

Click here to get full coverage on SMMT Electrified: A smarter route to decarbonisation is needed - SMMT

SMMT Electrified: A smarter route to decarbonisation is needed  SMMT

SMMT Electrified: A smarter route to decarbonisation is needed - SMMT

Click here to get full coverage on Motor trade body calls for review of UK's transition to zero-emission vehicles - IOM3

Motor trade body calls for review of UK's transition to zero-emission vehicles  IOM3

Motor trade body calls for review of UK's transition to zero-emission vehicles - IOM3

Click here to get full coverage on Summit Therapeutics (SMMT) Jumps 7.6% on Reports of $15-Billion AstraZeneca Deal - Yahoo Finance

Summit Therapeutics (SMMT) Jumps 7.6% on Reports of $15-Billion AstraZeneca Deal  Yahoo Finance

Summit Therapeutics (SMMT) Jumps 7.6% on Reports of $15-Billion AstraZeneca Deal - Yahoo Finance

Click here to get full coverage on Summit Therapeutics (SMMT) Is Down 21.0% After Mixed HARMONi Trial Data Raises Global Approval Questions - Yahoo Finance

Summit Therapeutics (SMMT) Is Down 21.0% After Mixed HARMONi Trial Data Raises Global Approval Questions  Yahoo Finance

Summit Therapeutics (SMMT) Is Down 21.0% After Mixed HARMONi Trial Data Raises Global Approval Questions - Yahoo Finance

Click here to get full coverage on Van market declines in November but EV demand grows - SMMT

Van market declines in November but EV demand grows  SMMT

Van market declines in November but EV demand grows - SMMT

Click here to get full coverage on SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca - Yahoo Finance

SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca  Yahoo Finance

SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca - Yahoo Finance

Click here to get full coverage on Wolfe Research Initiates Coverage on SMMT with 'Peer Perform' Ra - GuruFocus

Wolfe Research Initiates Coverage on SMMT with 'Peer Perform' Ra  GuruFocus

Wolfe Research Initiates Coverage on SMMT with 'Peer Perform' Ra - GuruFocus

Click here to get full coverage on Decarbonising HGVs needs focus - SMMT

Decarbonising HGVs needs focus - SMMT

Click here to get full coverage on EVs power up used car market in three-year growth run - SMMT

EVs power up used car market in three-year growth run  SMMT

EVs power up used car market in three-year growth run - SMMT

Click here to get full coverage on Summit Therapeutics (SMMT) Releases Financial Results and Updates on Operational Progress for Q3 2025 - Yahoo Finance

Summit Therapeutics (SMMT) Releases Financial Results and Updates on Operational Progress for Q3 2025  Yahoo Finance

Summit Therapeutics (SMMT) Releases Financial Results and Updates on Operational Progress for Q3 2025 - Yahoo Finance

Click here to get full coverage on SMMT announces new President – Paul Philpott, President and CEO, Kia UK - SMMT

SMMT announces new President – Paul Philpott, President and CEO, Kia UK  SMMT

SMMT announces new President – Paul Philpott, President and CEO, Kia UK - SMMT

Click here to get full coverage on Vehicle production down in January amid weak global markets - SMMT

Vehicle production down in January amid weak global markets  SMMT

Vehicle production down in January amid weak global markets - SMMT

Click here to get full coverage on New car market shrinks in August but EVs reach record share for the year - SMMT

New car market shrinks in August but EVs reach record share for the year  SMMT

New car market shrinks in August but EVs reach record share for the year - SMMT

Click here to get full coverage on SMMT Motor Industry Facts 2026 - SMMT

SMMT Motor Industry Facts 2026 - SMMT

Click here to get full coverage on New van demand dips slightly in September but best month ever for EV uptake - SMMT

New van demand dips slightly in September but best month ever for EV uptake  SMMT

New van demand dips slightly in September but best month ever for EV uptake - SMMT

Click here to get full coverage on Van market shrinks in 2025 despite EV growth - SMMT

Van market shrinks in 2025 despite EV growth  SMMT

Van market shrinks in 2025 despite EV growth - SMMT

Click here to get full coverage on Summit Therapeutics (SMMT) Stock on December 9, 2025: Trial Optimism Collides With High Risk, High Volatility - TechStock²

Summit Therapeutics (SMMT) Stock on December 9, 2025: Trial Optimism Collides With High Risk, High Volatility  TechStock²

Summit Therapeutics (SMMT) Stock on December 9, 2025: Trial Optimism Collides With High Risk, High Volatility - TechStock²

Click here to get full coverage on Tough year for Auto but new models and Industrial Strategy can deliver growth - SMMT

Tough year for Auto but new models and Industrial Strategy can deliver growth  SMMT

Tough year for Auto but new models and Industrial Strategy can deliver growth - SMMT

Click here to get full coverage on Cyber attack hits vehicle output with new risk arising from tax charge on auto workers - SMMT

Cyber attack hits vehicle output with new risk arising from tax charge on auto workers  SMMT

Cyber attack hits vehicle output with new risk arising from tax charge on auto workers - SMMT

Click here to get full coverage on September new car market delivers record number of EVs - SMMT

September new car market delivers record number of EVs  SMMT

September new car market delivers record number of EVs - SMMT

Click here to get full coverage on New car registrations stall in July but recovery expected - SMMT

New car registrations stall in July but recovery expected  SMMT

New car registrations stall in July but recovery expected - SMMT

Click here to get full coverage on Electric van demand doubles as overall market shrinks again - SMMT

Electric van demand doubles as overall market shrinks again  SMMT

Electric van demand doubles as overall market shrinks again - SMMT

Click here to get full coverage on SMMT Trade Report 2025 - SMMT

SMMT Trade Report 2025 - SMMT

Click here to get full coverage on UK new car market breaches two million as almost one in four buyers go electric - SMMT

UK new car market breaches two million as almost one in four buyers go electric  SMMT

SMMT

Price Chart

Key Statistics

Technicals

About SMMT

Latest News

SMMT warns HGV decarbonisation lagging behind targets despite growing investment - The Manufacturer

Summit Therapeutics (SMMT) Added to Citi 90-Day Upside Catalyst Call List - StreetInsider

Summit Therapeutics Inc. (SMMT) focused on non-small cell lung cancer trial of Ivonescimab - MSN

Advanced Charts

Top Gainers

Top Losers